Integrated approaches to understanding antipsychotic drug action at GPCRs

Current Opinion in Cell Biology

Volumn 27, Issue 1, 2014, Pages 56-62

  Urs, Nikhil M ^a   Nicholls, Peter J ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; QUINPIROLE; RISPERIDONE; TRANSCRIPTOME;

CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SCHIZOPHRENIA; TRANSCRIPTOMICS; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEOMICS; RECEPTORS, G-PROTEIN-COUPLED; TRANSCRIPTOME;

EID: 84890139617     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.11.002     Document Type: Review

References (80)

1. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci 1987, 10:19-40.
2. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283:397-401.
3. Birkmayer W., Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961, 73:787-788.
4. Delgado P.L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000, 61(Suppl 6):7-11.
5. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
6. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001, 41:237-260.
7. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr Opin Pharmacol 2004, 4:53-57.
8. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
9. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
10. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989, 251:238-246.
11. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
12. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
13. McFarland K., Price D.L., Bonhaus D.W. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behav Pharmacol 2011, 22:681-692.
14. Simon M.I., Strathmann M.P., Gautam N. Diversity of G proteins in signal transduction. Science 1991, 252:802-808.
15. Neves S.R., Ram P.T., Iyengar R. G protein pathways. Science 2002, 296:1636-1639.
16. Sheu Y.A., Kricka L.J., Pritchett D.B. Measurement of intracellular calcium using bioluminescent aequorin expressed in human cells. Anal Biochem 1993, 209:343-347.
17. Fitzgerald L.R., Mannan I.J., Dytko G.M., Wu H.L., Nambi P. Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay. Anal Biochem 1999, 275:54-61.
18. Adams S.R., Harootunian A.T., Buechler Y.J., Taylor S.S., Tsien R.Y. Fluorescence ratio imaging of cyclic AMP in single cells. Nature 1991, 349:694-697.
19. Ponsioen B., Zhao J., Riedl J., Zwartkruis F., van der Krogt G., Zaccolo M., Moolenaar W.H., Bos J.L., Jalink K. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep 2004, 5:1176-1180.
20. Xu Y., Piston D.W., Johnson C.H. A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc Natl Acad Sci U S A 1999, 96:151-156.
21. Barak L.S., Salahpour A., Zhang X., Masri B., Sotnikova T.D., Ramsey A.J., Violin J.D., Lefkowitz R.J., Caron M.G., Gainetdinov R.R. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol 2008, 74:585-594.
22. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., Harvey S.C., Donohue E., Hansen H.C., Andersson C.M., et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001, 299:268-276.
23. Newman-Tancredi A., Assie M.B., Leduc N., Ormiere A.M., Danty N., Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005, 8:341-356.
24. Newman-Tancredi A., Kleven M.S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011, 216:451-473.
25. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
26. Lohse M.J., Benovic J.L., Codina J., Caron M.G., Lefkowitz R.J. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990, 248:1547-1550.
27. Ferguson S.S., Downey W.E., Colapietro A.M., Barak L.S., Menard L., Caron M.G. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996, 271:363-366.
28. Luttrell L.M., Ferguson S.S., Daaka Y., Miller W.E., Maudsley S., Della Rocca G.J., Lin F., Kawakatsu H., Owada K., Luttrell D.K., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283:655-661.
29. Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., Luttrell L.M. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 2002, 277:9429-9436.
30. Ahn S., Shenoy S.K., Wei H., Lefkowitz R.J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 2004, 279:35518-35525.
31. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., Caron M.G. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 1999, 274:32248-32257.
32. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007, 28:416-422.
33. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
34. Bohn L.M., Gainetdinov R.R., Sotnikova T.D., Medvedev I.O., Lefkowitz R.J., Dykstra L.A., Caron M.G. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 2003, 23:10265-10273.
35. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
36. Masri B., Salahpour A., Didriksen M., Ghisi V., Beaulieu J.M., Gainetdinov R.R., Caron M.G. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A 2008, 105:13656-13661.
37. Klewe I.V., Nielsen S.M., Tarpo L., Urizar E., Dipace C., Javitch J.A., Gether U., Egebjerg J., Christensen K.V. Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology 2008, 54:1215-1222.
38. Bhatnagar A., Willins D.L., Gray J.A., Woods J., Benovic J.L., Roth B.L. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 2001, 276:8269-8277.
39. Schmid C.L., Raehal K.M., Bohn L.M. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 2008, 105:1079-1084.
40. Powell S.B., Geyer M.A. Overview of animal models of schizophrenia. Curr Protoc Neurosci 2007, 24. Chapter 9: Unit 9.
41. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
42. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., Aprille J.R., Dwyer D.S., Li X.M., Mahadik S.P., et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008, 60:358-403.
43. Weiner I., Lubow R.E., Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berl) 1984, 83:194-199.
44. King D.J. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998, 8:33-42.
45. Abi-Dargham A., Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005, 20:15-27.
46. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214-219.
47. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
48. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
49. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
50. Jaaro-Peled H. Gene models of schizophrenia: DISC1 mouse models. Prog Brain Res 2009, 179:75-86.
51. Allen J.A., Yost J.M., Setola V., Chen X., Sassano M.F., Chen M., Peterson S., Yadav P.N., Huang X.P., Feng B., et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A 2011, 108:18488-18493.
52. Kinkead B., Nemeroff C.B. Neurotensin, schizophrenia, and antipsychotic drug action. Int Rev Neurobiol 2004, 59:327-349.
53. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196:431-440.
54. Miyamoto S., Jarskog L.F., Fleischhacker W.W. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry 2013, 26:158-165.
55. McOmish C.E., Lira A., Hanks J.B., Gingrich J.A. Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain. Neuropsychopharmacology 2012, 37:2747-2755.
56. Bay-Richter C., O'Callaghan M.J., Mathur N., O'Tuathaigh C.M., Heery D.M., Fone K.C., Waddington J.L., Moran P.M. D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors. Neuropsychopharmacology 2013, 38:1512-1520.
57. Ralph-Williams R.J., Lehmann-Masten V., Otero-Corchon V., Low M.J., Geyer M.A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 2002, 22:9604-9611.
58. Bortolozzi A., Masana M., Diaz-Mataix L., Cortes R., Scorza M.C., Gingrich J.A., Toth M., Artigas F. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. Int J Neuropsychopharmacol 2010, 13:1299-1314.
59. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 2003, 425:917-925.
60. Lee K.W., Kim Y., Kim A.M., Helmin K., Nairn A.C., Greengard P. Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. Proc Natl Acad Sci U S A 2006, 103:3399-3404.
61. Gong S., Doughty M., Harbaugh C.R., Cummins A., Hatten M.E., Heintz N., Gerfen C.R. Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J Neurosci 2007, 27:9817-9823.
62. Bateup H.S., Santini E., Shen W., Birnbaum S., Valjent E., Surmeier D.J., Fisone G., Nestler E.J., Greengard P. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010, 107:14845-14850.
63. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
64. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 2008, 11:932-939.
65. Urs N.M., Snyder J.C., Jacobsen J.P., Peterson S.M., Caron M.G. Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci U S A 2012, 109:20732-20737.
66. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004, 101:5099-5104.
67. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007, 27:881-885.
68. Wadenberg M.L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 1996, 20:325-339.
69. Doyle J.P., Dougherty J.D., Heiman M., Schmidt E.F., Stevens T.R., Ma G., Bupp S., Shrestha P., Shah R.D., Doughty M.L., et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 2008, 135:749-762.
70. Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suarez-Farinas M., Schwarz C., Stephan D.A., Surmeier D.J., et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008, 135:738-748.
71. Sanz E., Yang L., Su T., Morris D.R., McKnight G.S., Amieux P.S. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci U S A 2009, 106:13939-13944.
72. Cloonan N., Forrest A.R., Kolle G., Gardiner B.B., Faulkner G.J., Brown M.K., Taylor D.F., Steptoe A.L., Wani S., Bethel G., et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods 2008, 5:613-619.
73. Bottomly D., Walter N.A., Hunter J.E., Darakjian P., Kawane S., Buck K.J., Searles R.P., Mooney M., McWeeney S.K., Hitzemann R. Evaluating gene expression in C57BL/6J and DBA/2J mouse striatum using RNA-Seq and microarrays. PLoS ONE 2011, 6:e17820.
74. MacDonald M.L., Eaton M.E., Dudman J.T., Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 2005, 57:1041-1051.
75. Thomas E.A., George R.C., Danielson P.E., Nelson P.A., Warren A.J., Lo D., Sutcliffe J.G. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 2003, 8:983-993. 950.
76. Gygi S.P., Aebersold R. Mass spectrometry and proteomics. Curr Opin Chem Biol 2000, 4:489-494.
77. Xiao K., McClatchy D.B., Shukla A.K., Zhao Y., Chen M., Shenoy S.K., Yates J.R., Lefkowitz R.J. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A 2007, 104:12011-12016.
78. Xiao K., Sun J., Kim J., Rajagopal S., Zhai B., Villen J., Haas W., Kovacs J.J., Shukla A.K., Hara M.R., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 2010, 107:15299-15304.
79. Choi-Rhee E., Schulman H., Cronan J.E. Promiscuous protein biotinylation by Escherichia coli biotin protein ligase. Protein Sci 2004, 13:3043-3050.
80. Roux K.J., Kim D.I., Raida M., Burke B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J Cell Biol 2012, 196:801-810.